CVS Health Corp. (CVS) shares rose 2.3% to $97.16 as of August 15, 2026, a modest gain from the prior close of $94.99. BestStocks flagged the session as a major change for CVS. Below, we break down what changed for CVS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
CVS climbed 2.3% to $97.16
CVS rose 2.3% in its latest session, moving from $94.99 to $97.16.
RiskCompany-Specific MoveLow confidence
Rel. volume
1.1×
Normal
Vs peers
Top 1 of 7 peers
Outperforming
Market cap
$124.0B
New York Stock Exchange
Analyst target
$110
+13.4% vs price
Price chart
Jul 15 – Aug 14
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for CVS Health Corp. investors
For CVS Health Corp. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 2.3% session move. Weighing against that: CVS Health fell 2.17% to $93.59 as investors absorbed disappointing preliminary 2027 profit guidance released last week, alongside ongoing regulatory scrutiny over its vertically integrated business model and persistent pressures in its pharmacy benefit manager segment; CVS Health Corp. moved -5.27% intraday from $104.42 to $98.92. Because the move outpaced peers, it looks driven by CVS-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $110.21, implying +13.4% upside from $97.16. BestStocks rates the overall signal quality low (56/100). With earnings roughly 81 days out, the next report is the most likely near-term test of the move.
CVS price reaction
CVS last traded at $97.16, up $2.17 (+2.28%) from the previous close of $94.99. The session traded on 1.1× average volume (normal), so participation was unremarkable. Its healthcare peer group moved a median -0.5% over the same stretch, leaving CVS ahead of the group by 2.8 points. Over the past month the stock has ranged between $93.50 and $110.60, and it currently sits about 21% of the way up that band.
Bullish and bearish analyst opinions on CVS Health Corp. (CVS)
The consensus analyst price target on CVS Health Corp. (CVS) is $110.21, 13.4% above the recent $97.16. Over the past 90 days analysts logged 0 upgrades, 15 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CVS line up.
▲ The bullish case
+Wall Street's consensus price target of $110.21 implies +13.4% upside from $97.16.
+The Street's most bullish target is $126.00 (+29.7%).
+Material positive event.
+Positive 2.3% session move.
+CVS Health Corp. (CVS) moved +0.36% from $95.33 to $95.67 on 2026-08-10.
▼ The bearish case
−The most bearish analyst target is $92.00 (-5.3%).
−CVS Health fell 2.17% to $93.59 as investors absorbed disappointing preliminary 2027 profit guidance released last week, alongside ongoing regulatory scrutiny over its vertically integrated business model and persistent pressures in its pharmacy benefit manager segment.
−CVS Health Corp. moved -5.27% intraday from $104.42 to $98.92.
−CVS Health Corp. (CVS) moved -2.52% from $104.72 to $102.08 on July 6, 2026.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 15, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
CVS Health Corp. (CVS) moved +2.71% from $94.60 to $97.16 on 2026-08-14. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a broader sector rally: peers MRK and PFE rose +2.20% and +1.82% respectively on the same day, and CVS volume remained near its 5-day average.
Activity2026-08-10-0.0%
CVS Health Corp. (CVS) moved +0.36% from $95.33 to $95.67 on 2026-08-10. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move coincided with CVS reaching a new 30-day low on below-average volume (0.6x the 5-day mean).
Activity2026-08-07-0.5%
CVS Health Corp. (CVS) moved +0.53% from $95.20 to $95.70 on 2026-08-07. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a broader sector drift, with healthcare peers PFE (+3.68%) and BMY (+1.71%) also gaining on the day; CVS reached a new 30-day low at $95.70 on near-average volume.
CVS Health stock fell 2.69% to $96.45 following Q2 2026 earnings released yesterday, during which the company beat profit expectations and raised 2026 guidance but issued early warnings about 2027. According to WSJ and Yahoo Finance, the selloff centered on management's cautious commentary regarding expected declines in Caremark pharmacy-benefit management membership due to new pricing contract models and insurer client pullbacks, alongside regulatory and cost pressures from the 340B drug-discount program. Volume at 2.58M shares (1.41x average at this point in session) is normal for the time of day.
Material / Earnings2026-08-05-5.1%
CVS Health Corp. (CVS) reported Q2 FY2026 EPS of $2.58 vs. consensus estimate of $1.87, beating by 38.0% on 2026-08-05.
Activity2026-08-05-5.1%
CVS Health Corp. (CVS) moved +5.76% from $93.72 to $99.12 on 2026-08-05. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide rally: three healthcare peers (AMGEN +7.64%, Pfizer +3.12%, Eli Lilly +4.33%) moved in the same direction, though CVS outperformed the peer average by 4.0 percentage points. Volume was 2.6x the 5-day average.
CVS Health Corp. moved -5.27% intraday from $104.42 to $98.92. CVS Health stock fell over 6% on August 5, 2026 , despite reporting second-quarter earnings of $2.58 per share (beating the $1.85 estimate) and raising its full-year profit outlook to $7.90–$8.10 per share. The drop was driven by cautious management warnings about elevated medical cost trends, 340B drug pricing program pressures, and preliminary 2027 guidance alongside expectations that its Caremark pharmacy benefit unit could lose members. Key Factors Behind the Stock Decline - Cautious Forward Commentary: Management warned of persistent medical cost trends and broader macroeconomic challenges, leading to a conservative outlook that offset the Q2 beat. - PBM Headwinds: Executives noted that the Caremark pharmacy benefit manager segment faces potential membership losses heading into next year. - Program Pressures: Company officials highlighted near-term profit drags from the federal 340B drug pricing program. - Profit-Taking: The stock had rallied significantly over the prior months leading up to the report, leaving it vulnerable to a pullback. If you'd like, we can look into: - Details on the new Eli Lilly weight-loss drug partnership announced with the earnings - How CVS's perfor
Filings2026-08-05-5.1%
CVS Health Corp. (CVS) filed a new 10-Q on August 5, 2026, disclosing financial results for the most recent quarter.
Upcoming catalysts & outlook
Next earnings
2026-11-04 (est.)
in 81 days
Thesis shift
Bullish Shift
bullish signal
Risk level
High
from change events
Frequently asked questions about CVS
Why did CVS Health Corp. (CVS) stock move?
CVS rose 2.3% to $97.16. No single company-specific catalyst was confirmed during the move window, and it looks like a company-specific move.
How much did CVS stock rise?
CVS gained 2.28% ($2.17) versus the prior close of $94.99, last trading at $97.16 on 1.1× average volume.
When is CVS Health Corp.'s next earnings date?
CVS's next earnings report is estimated for 2026-11-04 — about 81 days away.
What is the analyst price target for CVS?
The consensus analyst price target for CVS is $110.21, about 13.4% above the current $97.16. Over the past 90 days, analysts recorded 0 upgrades, 15 maintains, and 0 downgrades.
Is the CVS move company-specific or sector-wide?
BestStocks classifies it as a company-specific move: the peer group moved a median -0.5% against CVS's +2.3%. CVS ranks top 1 of 7 peers.
How BestStocks tracks CVS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CVS-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for CVS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 15, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
